Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lipson

Showing results (221-230 of 249) with videos related to

Pageof 25
Sort By:
Biorxiv : the Preprint Server for Biology|July 15, 2025
Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcomaEmma D Wrenn, Jacob C Harris, April A Apfelbaum, et al.
Respiratory Research|April 29, 2021
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbationsDave Singh, Gerard J Criner, Mark T Dransfield, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
Advances in Therapy|January 21, 2022
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|September 7, 2019
Misinterpretation of time-to-first event curves can lead to inappropriate treatmentBenjamin Hartley, Gerard J Criner, Mark T Dransfield, et al.
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Radiology|May 23, 2014
ResponseElissa R Price, Jonathan Hargreaves, Jafi A Lipson, et al.
Respiratory Research|June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialNicola C Day, Subramanya Kumar, Gerard Criner, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Pageof 25

Showing results (221-230 of 249) with videos related to

Sort By:
Pageof 25
Biorxiv : the Preprint Server for Biology|July 15, 2025
Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcomaEmma D Wrenn, Jacob C Harris, April A Apfelbaum, et al.
Respiratory Research|April 29, 2021
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbationsDave Singh, Gerard J Criner, Mark T Dransfield, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
Advances in Therapy|January 21, 2022
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|September 7, 2019
Misinterpretation of time-to-first event curves can lead to inappropriate treatmentBenjamin Hartley, Gerard J Criner, Mark T Dransfield, et al.
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Radiology|May 23, 2014
ResponseElissa R Price, Jonathan Hargreaves, Jafi A Lipson, et al.
Respiratory Research|June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialNicola C Day, Subramanya Kumar, Gerard Criner, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Pageof 25